Jyke Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.51 M
- Revenue Growth 13.39%
- Profit Growth 9.80%
- Ebitda 22.89%
- Net Worth 51.75%
- Total Assets 1.44%
About Jyke Pharmaceutical
Jyke Pharmaceutical Private Limited (JPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 December 2011 and has a history of 13 years and two months. Its registered office is in Gwalior, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.51 M.
Jai Mathur, Satyendra Jain, and Sahil Mathur serve as directors at the Company.
Company Details
-
Location
Gwalior, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232MP2011PTC027280
-
Company No.
027280
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Dec 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Jyke Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyendra Jain
|
Director | 30-Nov-2016 | Current |
|
Sahil Mathur
|
Director | 12-Dec-2011 | Current |
|
Jai Mathur
|
Director | 12-Dec-2011 | Current |
Financial Performance of Jyke Pharmaceutical.
Jyke Pharmaceutical Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 13.39% increase. The company also saw a slight improvement in profitability, with a 9.8% increase in profit. The company's net worth Soared by an impressive increase of 51.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jyke Pharmaceutical?
In 2017, Jyke Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nahata Agencies Private LimitedSatyendra Jain is a mutual person
-
Saffron Transformer Components Private Limited
Satyendra Jain is a mutual person
Charges (Loans)
₹1.51 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Oct 2022 | Hdfc Bank Limited | ₹1.51 M | Open |
How Many Employees Work at Jyke Pharmaceutical?
Unlock and access historical data on people associated with Jyke Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jyke Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jyke Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
